Gold Standard Diagnostics Announces Next Generation HE4 Ovarian Cancer Biomarker Testing Solutions
Published: Jun 13, 2012
DAVIS, Calif.--(BUSINESS WIRE)--Detection of the HE4 biomarker gives medical professionals an improved tool for early detection of ovarian cancer. Gold Standard Diagnostics (GSD) provides an exclusive HE4 EIA testing solution that is certified “ThunderBolt-Ready”ensuring seamless automation on GSD’s ThunderBolt™ EIA platform. HE4 testing enables healthcare professionals to detect ovarian cancer much earlier and increase the probability of cure to 90-95%1. Ovarian cancer is not the silent killer it was once thought to be.